Metraipolis › archive › dc_9a421e059def

Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib — Europe PMC PMID:41660509

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41660509
DOI
10.3389/fphar.2026.1714221
License (as archived)
solo-consultazione
Archived
2026-11-06T12:52:41.802Z
SHA-256 of the archived text
5ac21c734c926f747f7a39b645199a2d6874a25698540cd9bcbf4e40daaa4552
Stable URL of this page
https://metraipolis.com/documento/dc_9a421e059def

How to cite

Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib — Europe PMC PMID:41660509 — Europe PMC (en), https://europepmc.org/article/MED/41660509 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9a421e059def (Metraipolis archive dc_9a421e059def, sha256 5ac21c734c926f747f7a39b645199a2d6874a25698540cd9bcbf4e40daaa4552)
BibTeX
@misc{dc9a421e059def,
  title = {Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib — Europe PMC PMID:41660509},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41660509},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9a421e059def; sha256 5ac21c734c926f747f7a39b645199a2d6874a25698540cd9bcbf4e40daaa4552},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41660509. Agents can read the archived copy with the MCP tool read_document.